回盛生物 reported revenue of ¥0.86B for the period ended 2026-06-30, +5.2% year on year. Net income was ¥0.21B, a 23.9% net margin on a 35.7% gross margin. The largest revenue line is 兽用原料药及制剂 at 93% of the total. Free cash flow for the period was ¥-0.09B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.86B | +5.2% |
| Gross profit | ¥0.31B | — |
| Operating income | ¥0.23B | — |
| Net income | ¥0.21B | +75.6% |
| Gross margin | 35.7% | Net margin 23.9% |
| Revenue Q/Q | -11.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 兽用原料药及制剂 | ¥0.80B | 92.6% |
| 其他 | ¥0.06B | 7.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.56B | 64.3% |
| R&D | ¥0.05B | 6.2% |
| SG&A | ¥0.08B | 9.5% |
| Tax & other | ¥0.03B | 3.1% |
| Item | Amount |
|---|---|
| Total assets | ¥3.41B |
| Total liabilities | ¥1.08B |
| Shareholders' equity | ¥2.33B |
| Equity / assets | 68.2% |
| Operating cash flow | ¥0.08B |
| Capital expenditure | ¥0.16B |
| Free cash flow | ¥-0.09B |
| Cash conversion (OCF / net income) | 62% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
天阳科技 ・ 海晨股份 ・ 捷强装备 ・ 蒙泰高新 ・ 金春股份 ・ 维康药业 ・ 大叶股份 ・ 迦南智能 ・ 盛德鑫泰 ・ 万胜智能 ・ 龙利得 ・ 狄耐克
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies